Literature DB >> 22425929

Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed.

Daniel C Christoph1, Andreas-Claudius Hoffmann, Thomas C Gauler, Bernadette Reyna Asuncion, Heike Loewendick, Anja Peglow, Biftu Hassan, Cindy Tran, Murry W Wynes, Martin Schuler, Wilfried E Eberhard, Fred R Hirsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22425929      PMCID： PMC3358927          DOI： 10.1097/JTO.0b013e3182460fa9

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

1.  Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Authors:  Chung-Yu Chen; Yih-Leong Chang; Jin-Yuan Shih; Jou-Wei Lin; Kuan-Yu Chen; Chih-Hsin Yang; Chong-Jen Yu; Pan-Chyr Yang
Journal:  Lung Cancer       Date:  2011-03-01       Impact factor: 5.705

2.  Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Authors:  Jong-Mu Sun; Joungho Han; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

3.  Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

Authors:  Marta Pestrin; Silvia Bessi; Francesca Galardi; Mara Truglia; Annibale Biggeri; Chiara Biagioni; Silvia Cappadona; Laura Biganzoli; Augusto Giannini; Angelo Di Leo
Journal:  Breast Cancer Res Treat       Date:  2009-07-12       Impact factor: 4.872

4.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

5.  Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and rt-PCR.

Authors:  Junming Guo; Feng Yao; Yanlu Lou; Changfeng Xu; Bingxiu Xiao; Wenhong Zhou; Jian Chen; Yaoren Hu; Zhong Liu
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

6.  Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type.

Authors:  Dena Marrinucci; Kelly Bethel; Madelyn Luttgen; Richard H Bruce; Jorge Nieva; Peter Kuhn
Journal:  Arch Pathol Lab Med       Date:  2009-09       Impact factor: 5.534

7.  Circulating tumor cells, enumeration and beyond.

Authors:  Jian-Mei Hou; Matthew Krebs; Tim Ward; Karen Morris; Robert Sloane; Fiona Blackhall; Caroline Dive
Journal:  Cancers (Basel)       Date:  2010-06-09       Impact factor: 6.639
  7 in total
  2 in total

Review 1.  Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.

Authors:  Lei Wang; Coraline Dumenil; Catherine Julié; Violaine Giraud; Jennifer Dumoulin; Sylvie Labrune; Thierry Chinet; Jean-François Emile; Biao He; Etienne Giroux Leprieur
Journal:  Oncotarget       Date:  2017-11-23

2.  EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma.

Authors:  Andreas-Claudius Hoffmann; Eray Goekkurt; Peter V Danenberg; Sylvia Lehmann; Gerhard Ehninger; Daniela E Aust; Jan Stoehlmacher-Williams
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.